Research profile · Blends
Cagrilintide + Semaglutide
Amylin analogue + GLP-1 receptor agonist (CagriSema)
Available as: 2.5mg+2.5mg, 5mg+5mg
Overview
A combination of cagrilintide and semaglutide, studied by Novo Nordisk as a single co-formulated weekly treatment.
Mechanism
Pairs two complementary satiety pathways: amylin receptor signalling in the hindbrain and GLP-1 receptor signalling in the hypothalamus and gut.
Research highlights
- Phase 2 in type 2 diabetes: greater glycaemic and weight effects than either component alone.
- Phase 3 REDEFINE programme: evaluated for chronic weight management and type 2 diabetes.
Compound data
- Components
- Cagrilintide + Semaglutide